SCHEDULE 13G 0001100397 XXXXXXXX LIVE Common Stock, par value $0.001 per share 04/09/2025 0001795091 OS Therapies Incorporated 68764Y207 115 Pullman Crossing Road, Suite #103 Grasonville MD 21638 Rule 13d-1(c) AYALA PHARMACEUTICALS, INC. DE 2164215.00 0.00 2164215.00 0.00 2164215.00 N 9.99 CO With regard to Rows (5), (7) and (9), please see Item 4. Row (11) is based on 21,663,811 shares of Common Stock reported as outstanding as of March 28, 2025 in the Issuer's Annual Report on Form 10-K, filed with the SEC on March 31, 2025. OS Therapies Incorporated 115 Pullman Crossing Road, Suite #103, Grasonville, MD, 21638 Ayala Pharmaceuticals, Inc. ("Ayala") 21 Brownlee Place, Suite # 327 Basking Ridge, NJ 07920-9998 United States Y 2,164,215 shares of Common Stock. Such shares exclude (i) a warrant issued to Ayala to purchase 2,166,381 shares of Common Stock (the "Warrant" and the shares of Common Stock issuable thereunder, the "Warrant Shares") and (ii) subject to obtaining approval of the stockholders of the Issuer, issuance to Ayala of an additional 444,041 shares of Common Stock (the "Additional Consideration Shares"). The Warrant may not be exercised to the extent that the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the "Beneficial Ownership Limitation"), which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. Accordingly, subject to the Beneficial Ownership Limitation and said stockholder approval, Ayala may be deemed to beneficially own the Warrant Shares and the Additional Consideration Shares. See Row (11) of the cover page of the Reporting Person above. See Row (5) of the cover page of the Reporting Person above and note in Item 4 above 0 See Row (7) of the cover page of the Reporting Person above and note in Item 4 above. 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. AYALA PHARMACEUTICALS, INC. /s/ Sarit Steinberg 04/16/2025